Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Shanghai Henlius Biotech
Company

Shanghai Henlius Biotech

Tracked across 1 events · 7 articles · First seen Feb 05, 2026 · Last active Feb 05, 2026

Sentiment
70
Attention
4
Events
1
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Business
Eisai Licenses Serplulimab from Shanghai Henlius Biotech for Japan
Shanghai Henlius Biotech, Inc. has entered into a licensing agreement with Eisai for serplulimab in Japan, receiving an upfront payment of USD 75 million, potential milestone payments, and double-digit royalties. This agreement expands the global reach of its innovative anti-PD-1 antibody and leverages Eisai's commercial expertise in Japan.
Feb 05, 2026 · 7 articles
Relationships (2)
Eisai partner ↔ Shanghai Henlius Biotech Eisai and Shanghai Henlius Biotech, Inc. are collaborating on serplulimab in Jap
Jason Zhu CEO ↔ Shanghai Henlius Biotech Jason Zhu is the CEO of Shanghai Henlius Biotech, Inc.
NEWSDESK
Track Shanghai Henlius Biotech live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.